All Stories

  1. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort
  2. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort
  3. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  4. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  5. Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis
  6. Liver Assessment in Patients with Ataxia-Telangiectasia: Transient Elastography Detects Early Stages of Steatosis and Fibrosis
  7. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al
  8. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B
  9. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection
  10. Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes
  11. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
  12. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus
  13. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
  14. Transportation and handling of blood samples prior to ammonia measurement in the real life of a large university hospital
  15. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta
  16. Posters
  17. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease
  18. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
  19. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease
  20. Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection
  21. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography
  22. Liver Fibrosis Determination
  23. External validation of an algorithm combining multi‐analyte blood tests (FibroTest‐LCR1‐LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease
  24. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
  25. Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' reply
  26. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis
  27. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing
  28. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
  29. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
  30. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
  31. Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis
  32. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study
  33. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort
  34. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference
  35. Impact of steatosis and inflammation definitions on the performance of NASH tests
  36. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective
  37. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
  38. Cystic Fibrosis–related Liver Disease
  39. Impact of graft preservation solutions for liver transplantation on early cytokine release and postoperative organ dysfunctions. A pilot study
  40. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis
  41. Chronic hepatitis E in HIV/HBV coinfected patient
  42. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis
  43. Screening studies of transient elastography and FibroTest in the general population
  44. NAFLD and liver transplantation: Current burden and expected challenges
  45. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
  46. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
  47. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease
  48. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients
  49. Fatty liver is an independent predictor of early carotid atherosclerosis
  50. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion
  51. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury
  52. Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection
  53. Critical comparison of elastography methods to assess chronic liver disease
  54. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
  55. Rate of employment after liver transplantation in France
  56. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
  57. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
  58. Hepatitis E infection in patients with severe alcoholic hepatitis
  59. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study
  60. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
  61. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
  62. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
  63. Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study
  64. Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants
  65. Spontaneous ascitic fluid infection and bacteremia due to Yersinia pseudotuberculosis in a liver transplant patient
  66. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards
  67. Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding
  68. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases
  69. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic
  70. Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms
  71. Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests
  72. Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification
  73. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease
  74. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)
  75. Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival
  76. Impact of common risk factors of fibrosis progression in chronic hepatitis C
  77. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
  78. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: “APRI c’est fini ?”
  79. Spleen Stiffness Measurement by Transient Elastography to Diagnose Portal Hypertension in Children
  80. Biopsy as well as FibroTest/Fibrosure Is Suboptimal for Discriminating Intermediate Fibrosis Stages in Patients With Chronic Hepatitis B
  81. Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
  82. FibroTest (FT) has similar accuracy for cirrhosis in ‘intention-to-diagnose’ which is superior to transient elastography (TE) in chronic hepatitis B.
  83. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
  84. The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
  85. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
  86. Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection
  87. Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235]
  88. Correction
  89. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up
  90. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
  91. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
  92. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
  93. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis
  94. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
  95. The use of transient elastography and non-invasive serum markers of fibrosis in pediatric liver transplant recipients
  96. Chronic hepatitis C virus (HCV) disease burden and cost in the United States
  97. Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard
  98. Liver Stiffness, Platelets, and Spleen Size Is Reliable in Nondecompensated Cirrhotic Patients
  99. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin
  100. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study
  101. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease
  102. Optimal nonsurgical management of peptic ulcer bleeding, including arterial embolization is associated with a mortality below 1%
  103. Interferon‐gamma with peginterferon alpha‐2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)
  104. Reply
  105. Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection
  106. Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C
  107. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
  108. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
  109. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection
  110. Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study
  111. Cost-effectiveness modeling of colorectal cancer: Computed tomography colonography vs colonoscopy or fecal occult blood tests
  112. Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis
  113. Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis?
  114. Gastric mucormycosis: A rare cause of gastrointestinal bleeding in cirrhosis
  115. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers
  116. Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
  117. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard
  118. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab
  119. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis
  120. Touching some firm ground in the epidemiology of NASH
  121. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis
  122. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
  123. FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
  124. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis
  125. The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test
  126. Recombinant activated factor VII in chronic liver diseases: Should we be afraid of thromboembolic events?
  127. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI)
  128. FibroStic: A large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted
  129. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
  130. Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C
  131. Ranking Hepatologists: Which Hirsch's h-Index to prevent the “e-crise de foi-e”?
  132. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
  133. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  134. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy
  135. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
  136. Perioperative management of combined heart-liver transplantation in patients with cirrhosis, renal insufficiency, or pulmonary hypertension
  137. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program
  138. Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis
  139. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease
  140. High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France
  141. Early Use of TIPS for Cirrhosis and Variceal Bleeding
  142. Hirsch Index and Truth Survival in Clinical Research
  143. A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C
  144. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure
  145. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
  146. Interferon   receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
  147. Assessment of adrenal function in cirrhotic patients: Salivary cortisol should be preferred
  148. Toxicité hépatique de la chimiothérapie du cancer colorectal métastatique: revue de la littérature
  149. Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced Cirrhosis
  150. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
  151. Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso
  152. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
  153. Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation
  154. Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers
  155. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
  156. Evaluation of FibroTest–ActiTest in children with chronic hepatitis C virus infection
  157. Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre
  158. Perspectives on fibrosis progression in hepatitis C: an á la carte approach to risk factors and staging of fibrosis
  159. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C
  160. Similarities and Differences Between REPEAT and EPIC3
  161. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy
  162. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials
  163. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
  164. Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV
  165. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?
  166. Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography
  167. Stéatohépatite métabolique : 30 ans de recherches qui ont changé la NASH
  168. Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B
  169. Liver biopsy: The best standard…when everything else fails
  170. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
  171. The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050–60: “Evaluation and improvement of a reliable diagnosis of cirrhosis by ...
  172. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure
  173. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus
  174. Immediate Listing for Liver Transplantation Versus Standard Care for Child–Pugh Stage B Alcoholic Cirrhosis
  175. Discordance between results of biomarkers of fibrosis shows that it is at least a “ménage à deux”
  176. Applicability and variability of liver stiffness measurements according to probe position
  177. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
  178. Perisinusoidal cells (Ito-cells) enlargement in a family with myotonic dystrophy
  179. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions
  180. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
  181. Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
  182. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency
  183. FibroTest-ActiTest as a non-invasive marker of liver fibrosis
  184. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update
  185. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
  186. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease
  187. An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
  188. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
  189. Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes
  190. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma
  191. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence
  192. Adhésion à la bithérapie pégylée au cours de l’hépatite chronique C
  193. Évaluation non-invasive de la fibrose hépatique au cours de l’hépatite C
  194. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers
  195. Assessment of liver fibrosis: Noninvasive means
  196. Chapter 4 Biomarkers Of Liver Fibrosis
  197. Nodular regenerative hyperplasia: The main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities
  198. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C
  199. Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir
  200. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats
  201. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
  202. Meta-analyses of FibroTest diagnostic value in chronic liver disease
  203. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C
  204. FibroMAX™: towards a new universal biomarker of liver disease?
  205. Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages
  206. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C
  207. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability
  208. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
  209. Relationship between the Fibrotest and portal hypertension in patients with liver disease
  210. Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial
  211. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC)
  212. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
  213. Relapse rate of patients after healing of oesophagitis-a prospective study of alginate as self-care treatment for 6 months
  214. Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study
  215. Peut-on traiter la stéatohépatite métabolique ?
  216. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
  217. Faut-il encore faire des biopsies du foie ?
  218. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
  219. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
  220. Association between Leptin, Metabolic Factors and Liver Histology in Patients with Chronic Hepatitis C
  221. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
  222. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
  223. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia
  224. A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C
  225. Erratum
  226. Fibrosis as an End Point for Clinical Trials in Liver Disease: A Report of the International Fibrosis Group
  227. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
  228. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis
  229. Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection
  230. Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?
  231. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease
  232. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
  233. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine
  234. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study
  235. Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant Variants
  236. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers
  237. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level
  238. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
  239. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL)
  240. A novel dendritic cell subset involved in tumor immunosurveillance
  241. Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores
  242. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious
  243. Blood oxidative stress markers are unreliable markers of hepatic steatosis
  244. Diagnostic value of FibroTest with normal serum aminotransferases
  245. Natural history and predictors of disease severity in chronic hepatitis C
  246. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
  247. Lamivudine and HBV-associated nephropathy
  248. A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients
  249. FAS promoter polymorphisms correlate with activity grade in hepatitis C patients
  250. Longitudinal Assessment of Histology Surrogate Markers (FibroTest-ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection
  251. A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B
  252. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
  253. Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy?
  254. Caution before embracing serum markers of liver fibrosis in clinical practice
  255. Management of chronic hepatitis C in French departments of internal medicine and infectious diseases
  256. Age and gender will survive to competing risks as fibrosis factors
  257. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease
  258. Reply:
  259. A reference material for traceability of aspartate aminotransferase (AST) results
  260. FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis?
  261. NASH: a hidden and silent fibroser finally revealed?
  262. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure
  263. Long-term outcome improvement in patients with chronic hepatitis D treated with interferon α
  264. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
  265. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection
  266. The rising health and economic burden of chronic hepatitis C
  267. Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C
  268. Treatment of Hepatitis C Virus: The First Decade
  269. The elusiveness of “normal” ALT in fatty liver
  270. Comparing the public health burden of chronic hepatitis C and HIV infection in France
  271. The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV
  272. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
  273. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
  274. Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
  275. Fat, diabetes, and liver injury in chronic hepatitis C
  276. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
  277. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure
  278. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
  279. The burden cost of French patients suffering from irritable bowel syndrome
  280. Treatment of cirrhotic patients in the pegylated interferon era
  281. Fibrogenic impact of high serum glucose in chro nic hepatitis C
  282. Viral hepatitis B
  283. Viral hepatitis C
  284. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules
  285. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C
  286. Worsening of steatosis and fibrosis progression
  287. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
  288. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B
  289. Reversal of cirrhosis: evidence-based medicine?
  290. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
  291. Sarcoidosis and interferon therapy: report of five cases and review of the literature
  292. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence
  293. Noninvasive prediction of fibrosis in patients with chronic hepatitis C
  294. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial
  295. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
  296. Acupuncture for gastrointestinal disorders
  297. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C
  298. A comparison of fibrosis progression in chronic liver diseases
  299. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients
  300. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C
  301. PEG-interferon versus conventional interferon and liver fibrosis: Do we have evidence of superiority?
  302. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection
  303. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C
  304. Truth Survival
  305. Truth Survival
  306. Portal lymphocytic infiltrate in alcoholic liver disease
  307. Les interférons ont-ils une action antifibrosante ?Le point de vue de l'hépatologue
  308. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection
  309. Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  310. Corrigendum to “Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C” [J Hepatol 36 (2002) 812–818]
  311. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study
  312. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C
  313. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients
  314. NNRTI-related or -unrelated hepatotoxicity?
  315. Fatigue in patients with chronic hepatitis C
  316. Truth Survival in Clinical Research: An Evidence-Based Requiem?
  317. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C
  318. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis
  319. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
  320. Individual and evidence-based
  321. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study
  322. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel
  323. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH
  324. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns
  325. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis
  326. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial
  327. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
  328. Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis
  329. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model
  330. Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*
  331. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study
  332. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient
  333. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
  334. Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy
  335. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
  336. The role of interleukin-10 in severe acute alcoholic hepatitis
  337. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
  338. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
  339. Une hépatite à cytomégalovirus n’est jamais chronique, et peut en cacher une autre !
  340. Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis
  341. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update
  342. Chronic hepatitis B treatment with lamivudine in kidney transplant patients
  343. Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C
  344. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report
  345. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C
  346. Estimating future hepatitis C morbidity, mortality, and costs in the United States
  347. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis c
  348. Liver fibrosis in overweight patients
  349. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids
  350. Natural history of HCV infection
  351. Appropriateness of Liver Biopsy
  352. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
  353. Is an ?� la carte? combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
  354. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections
  355. EFFECT OF INTERFERON THERAPY ON THE NATURAL HISTORY OF HEPATITIS C VIRUS-RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
  356. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
  357. Extrahepatic manifestations of chronic hepatitis C
  358. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
  359. Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences
  360. A short induction regimen of interferon-α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial
  361. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe
  362. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis
  363. Response to interferon alpha  treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus
  364. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge
  365. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis
  366. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival
  367. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring
  368. Summary of the first international symposium on viral hepatitis
  369. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
  370. Impact of hepatitis B and C virus on kidney transplantation outcome
  371. Diurnal variation of serum alanine transaminase activity in chronic liver disease
  372. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  373. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  374. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis
  375. No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia
  376. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease
  377. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C
  378. Hepatitis C: Somber views of natural history and optimistic views of interferon treatment?
  379. Management of hepatitis C
  380. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro- oesophageal reflux
  381. Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis?
  382. Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis
  383. Thierry Poynard
  384. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
  385. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin
  386. In situ detection of lipid peroxidation by-products in chronic liver diseases
  387. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitisC virus
  388. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features.
  389. Review article: critical review of meta-analyses of randomized clinical trials in hepatogastroenterology
  390. Natural history of liver fibrosis progression in patients with chronic hepatitis C
  391. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis
  392. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis
  393. Histological features predictive of liver fibrosis in chronic hepatitis C infection.
  394. Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases
  395. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
  396. An algorithm for the grading of activity in chronic hepatitis C
  397. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial
  398. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
  399. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix
  400. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix
  401. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease
  402. Heptitis B and C virus infection in HBsAg-negative alcoholics without i.v. drug abuse or previous blood transfusions
  403. A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis
  404. Transforming growth factor?beta 1 (TGF-?1) and TGF-?1 receptors in normal, cirrhotic, and neoplastic human livers*1
  405. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients
  406. Prevalence of Cholelithiasis According to Alcoholic Liver Disease: A Possible Role of Apolipoproteins AI and AII
  407. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine
  408. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy
  409. Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis
  410. Alpha-2-macroglobulin and hepatic fibrosis
  411. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls
  412. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis
  413. Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: Localization and association with progression of liver fibrosis
  414. A Two-centre, Randomized, Double-blind Trial of Ornithine Oxoglutarate in 194 Elderly, Ambulatory, Convalescent Subjects
  415. No effect of neutralizing antibody to TGF-β1 in acute CC14-induced liver fibrogenesis
  416. Diaphragm Function Is Not Impaired by Pneumoperitoneum After Laparoscopy
  417. Laparoscopic treatment without cholecystectomy for gallbladder perforation after liver biopsy
  418. Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.
  419. Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial
  420. Prednisolone in Severe Alcoholic Hepatitis
  421. Cirrhosis as an independent risk factor for colonic adenomas.
  422. A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis
  423. Anti—pre-S responses and viral clearance in chronic hepatitis B virus infection
  424. Autoimmune Chronic Hepatitis Exacerbated by Alpha-Interferon
  425. Computer-Aided Decision Support in Hepatology
  426. Portal hypertensive colopathy
  427. Reply
  428. Prevention of Gastrointestinal Bleeding in Cirrhosis
  429. Trauma in Cirrhosis: An Indicator of the Pattern of Alcohol Abuse in Different Societies
  430. Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices
  431. Devenir des patients après guérison d’une œsophagite Etude prospective de 1 030 patients pendant 6 mois
  432. Independent risk factors for hepatocellular carcinoma in french drinkers
  433. A biphasic pattern of anti-pre-s responses in acute hepatitis B virus infection
  434. Serum Apolipoprotein A-I in Alcoholic Patients with Chronic Calcifying Pancreatitis
  435. β-blockers and variceal haemorrhage
  436. Long-term results of treatment of vascular malformations of the gastrointestinal tract by neodymium YAG laser photocoagulation
  437. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis
  438. Apolipoproteinemia A and α-fetoprotein in the diagnosis of hepatocellular carcinoma and cirrhosis: Several interpretations
  439. Diagnostic Value of Serum gamma-Glutamyl-Transferase Activity and Mean Corpuscular Volume in Alcoholic Patients with or without Cirrhosis
  440. Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer
  441. Expression of histocompatibility antigens and characterization of the lymphocyte infiltrate in hyperplastic polyps of the large bowel
  442. Statistics in clinical trials
  443. Randomized Double-Blind Clinical Trial of Aluminum Phosphate versus Ranitidine in the Acute Treatment of Duodenal Ulcer
  444. Serial passage of West-European sporadic non-A non-B hepatitis in rhesus monkeys by inoculation with fecal extracts
  445. Apolipoprotein A1 is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients
  446. Endoscopic Nd-YAG laser therapy for palliative treatment of colorectal adenocarcinoma: A multivariate prognostic analysis
  447. Endoscopic laser therapy for duodenal villous adenoma
  448. A randomized study of a coaxial fiber versus a naked fiber for endoscopic Nd:YAG laser therapy of esophageal and rectal tumors
  449. Successful ablation of a large fibrovascular polyp of the esophagus by endoscopic Nd:YAG laser therapy
  450. RECTAL AND COLONIC VARICES IN CIRRHOSIS
  451. A Randomised Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis
  452. Prognostic evaluation in cirrhosis
  453. Detection of hepatitis B surface antigen by a monoclonal radioimmunoassay in the serum of alcoholic patients
  454. Response to hewitt et al: Retrieval of randomized clinical trials in liver disease
  455. A DECADE OF CAMPYLOBACTER PYLORI
  456. Observer Variation in Assessment of Liver Biopsies of Alcoholic Patients
  457. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis
  458. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding
  459. Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis
  460. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol
  461. Gastric phytobezoar destruction by Nd:YAG laser therapy
  462. Apolipoprotein AI and alcoholic liver disease
  463. Multivariate analysis of prognostic factors in fulminant hepatitis B
  464. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives
  465. A randomized clinical trial of supplementary parenteral nutrition in jaundiced alcoholic cirrhotic patients
  466. The retrieval of randomized clinical trials in liver disease from the medical literature
  467. Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients
  468. Psoriasis, alcohol, and liver disease.
  469. Relationships between liver histologic lesions and portal hypertension in patients with alcoholic cirrhosis
  470. Propranolol for prevention of recurrent GI bleeding
  471. Adrenocorticosteroid administration and peptic ulcer: A critical analysis
  472. A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report
  473. HEPATITIS B VACCINE: A DIAGNOSTIC TEST FOR PREVIOUS HEPATITIS B VIRUS INFECTION?
  474. Prognostic Value of Total Serum Bilirubin/γ-Glutamyl Transpeptidase Ratio in Cirrhotic Patients
  475. Adrenocorticosteroid Therapy and Peptic-Ulcer Disease
  476. Efficiency of respiratory assistance in cirrhotic patients with liver failure
  477. Recurrent bleeding and propranolol?
  478. Relations Between Effectiveness of a Diagnostic Test, Prevalence of the Disease, and Percentages of Uninterpretable Results
  479. Secretory Diarrhea and Prostaglandin D2Overproduction in Systemic Mastocytosis
  480. Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: Assessment by the artificial pancreas
  481. Propranolol in Gastrointestinal Bleeding from Cirrhosis
  482. Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis
  483. Upper digestive tract hemorrhage in cirrhotic patients
  484. PECTIN EFFICACY IN INSULIN-TREATED DIABETICS ASSESSED BY THE ARTIFICIAL PANCREAS
  485. Hepatocellular Carcinoma in NAFLD
  486. Alcoholic Liver Disease
  487. Progression of Fibrosis